Contact Number:
Email:
Andrew is a Natural Sciences graduate from the University of Cambridge, majoring in chemistry with first class honours, and has a DPhil degree in protein NMR from the University of Oxford. Andrew has spent more than 30 years formulating and executing IP strategies in the pharmaceutical industry, having worked in-house for 10 years in the IP departments of Fisons (now Sanofi), Astra Pharmaceuticals (now AstraZeneca), Glaxo Wellcome and GlaxoSmithKline prior to founding Sagittarius IP in 2002. Current clients include many small privately financed biotech firms, big-pharma corporations and venture capital firms.
Andrew has experience in all aspects of biotechnology, chemical and pharmaceutical patent practice including patent filing strategy, patent drafting, prosecution and enforcement. His subject matter specialisms include medicinal chemistry, formulation of small and large molecules, antibody technology, T-cell receptors, vaccines, therapeutic proteins and nucleic acids, radiopharmaceuticals, inhaled medicines and diagnostics. Andrew is expert in understanding regulatory based exclusivity periods for pharmaceutical products. He also specialises in handling IP due diligence and related contract issues associated with licence agreements or investments. Andrew has experience of multinational litigation, principally gained in USA, Japan, France, South Africa and the UK, and has particular experience in handling EPO oppositions and appeals. His EPO opposition experience includes numerous high value cases concerning formulations, processes, salt forms and crystalline polymorphs.
Andrew has an active interest in IP education and training; he is a former member of CIPA’s Education Committee. Andrew is based in our Marlow and London offices.
Contact Number:
Email:
Andrew is a Natural Sciences graduate from the University of Cambridge, majoring in chemistry with first class honours, and has a DPhil degree in protein NMR from the University of Oxford. Andrew has spent more than 30 years formulating and executing IP strategies in the pharmaceutical industry, having worked in-house for 10 years in the IP departments of Fisons (now Sanofi), Astra Pharmaceuticals (now AstraZeneca), Glaxo Wellcome and GlaxoSmithKline prior to founding Sagittarius IP in 2002. Current clients include many small privately financed biotech firms, big-pharma corporations and venture capital firms.
Andrew has experience in all aspects of biotechnology, chemical and pharmaceutical patent practice including patent filing strategy, patent drafting, prosecution and enforcement. His subject matter specialisms include medicinal chemistry, formulation of small and large molecules, antibody technology, T-cell receptors, vaccines, therapeutic proteins and nucleic acids, radiopharmaceuticals, inhaled medicines and diagnostics. Andrew is expert in understanding regulatory based exclusivity periods for pharmaceutical products. He also specialises in handling IP due diligence and related contract issues associated with licence agreements or investments. Andrew has experience of multinational litigation, principally gained in USA, Japan, France, South Africa and the UK, and has particular experience in handling EPO oppositions and appeals. His EPO opposition experience includes numerous high value cases concerning formulations, processes, salt forms and crystalline polymorphs.
Andrew has an active interest in IP education and training; he is a former member of CIPA’s Education Committee. Andrew is based in our Marlow and London offices.
Andrew is a Natural Sciences graduate from the University of Cambridge, majoring in chemistry with first class honours, and has a DPhil degree in protein NMR from the University of Oxford. Andrew has spent more than 30 years formulating and executing IP strategies in the pharmaceutical industry, having worked in-house for 10 years in the IP departments of Fisons (now Sanofi), Astra Pharmaceuticals (now AstraZeneca), Glaxo Wellcome and GlaxoSmithKline prior to founding Sagittarius IP in 2002. Current clients include many small privately financed biotech firms, big-pharma corporations and venture capital firms.
Andrew has experience in all aspects of biotechnology, chemical and pharmaceutical patent practice including patent filing strategy, patent drafting, prosecution and enforcement. His subject matter specialisms include medicinal chemistry, formulation of small and large molecules, antibody technology, T-cell receptors, vaccines, therapeutic proteins and nucleic acids, radiopharmaceuticals, inhaled medicines and diagnostics. Andrew is expert in understanding regulatory based exclusivity periods for pharmaceutical products. He also specialises in handling IP due diligence and related contract issues associated with licence agreements or investments. Andrew has experience of multinational litigation, principally gained in USA, Japan, France, South Africa and the UK, and has particular experience in handling EPO oppositions and appeals. His EPO opposition experience includes numerous high value cases concerning formulations, processes, salt forms and crystalline polymorphs.
Andrew has an active interest in IP education and training; he is a former member of CIPA’s Education Committee. Andrew is based in our Marlow and London offices.
Andrew is a Natural Sciences graduate from the University of Cambridge, majoring in chemistry with first class honours, and has a DPhil degree in protein NMR from the University of Oxford. Andrew has spent more than 30 years formulating and executing IP strategies in the pharmaceutical industry, having worked in-house for 10 years in the IP departments of Fisons (now Sanofi), Astra Pharmaceuticals (now AstraZeneca), Glaxo Wellcome and GlaxoSmithKline prior to founding Sagittarius IP in 2002. Current clients include many small privately financed biotech firms, big-pharma corporations and venture capital firms.
Andrew has experience in all aspects of biotechnology, chemical and pharmaceutical patent practice including patent filing strategy, patent drafting, prosecution and enforcement. His subject matter specialisms include medicinal chemistry, formulation of small and large molecules, antibody technology, T-cell receptors, vaccines, therapeutic proteins and nucleic acids, radiopharmaceuticals, inhaled medicines and diagnostics. Andrew is expert in understanding regulatory based exclusivity periods for pharmaceutical products. He also specialises in handling IP due diligence and related contract issues associated with licence agreements or investments. Andrew has experience of multinational litigation, principally gained in USA, Japan, France, South Africa and the UK, and has particular experience in handling EPO oppositions and appeals. His EPO opposition experience includes numerous high value cases concerning formulations, processes, salt forms and crystalline polymorphs.
Andrew has an active interest in IP education and training; he is a former member of CIPA’s Education Committee. Andrew is based in our Marlow and London offices.
